Intratech Medical · raw details

Intratech Medical is developing the Booster balloon catheter therapy to treat patients with acute myocardial infarction by reducing infarct size, thereby improving clinical outcomes. The Booster balloon aims to disrupt the last frontier in ischemic heart disease management and to improve the lives of millions of people worldwide while lowering the associated healthcare costs. Each year approximately 16 million people worldwide will have a heart attack caused by the narrowing or blockage of the coronary arteries supplying blood to the heart muscle. About 6 million of these patients will have an acute myocardial infarction (AMI) requiring immediate revascularization of the clogged artery, which is performed by percutaneous coronary intervention (PCI). Even after a successful revascularization of the patients coronary arteries, in up to 30% of patients the ischemic area around the infarcted heart muscle may still grow and convert into scar tissue, resulting in higher rates of heart failure and mortality. Intratech Medical has had promising preclinical results and is launching its first-in-human clinical study in 2021.